Interventions for managing ADHD include medications, such as stimulants (methylphenidate and amphetamines) and non-stimulants (eg, atomoxetine, bupropion, clonidine, guanfacine, and viloxazine), as well as non-pharmacological approaches such as behavioural therapies, dietary interventions, and neurofeedback. Current guidelines generally recommend medication—typically stimulants as first-line treatment and non-stimulants as second-line—combined with behavioural or cognitive behavioural therapies. Although many meta-analyses of randomised controlled trials have assessed ADHD treatments, their usefulness for clinicians is limited. They often focus on narrow outcomes, show conflicting results for the same interventions, and frequently do not assess evidence quality. Additionally, findings are mainly published in academic journals, limiting accessibility for people with ADHD, who have called for clearer, evidence-based online resources.
Target Audience: Physicians (psychiatrists, pediatricians, child neurologists), psychologists, social workers, other mental health clinicians and researchers, and students and trainees.
Upon completion of this activity, participants will be able to:
- Use EBI-ADHD in clinical practice and research